Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/27/2012WO2012154122A3 A topical formulation for treatment of hyperkeratotic skin
12/27/2012WO2012151559A3 Cytotoxic therapy by proton flux modulation
12/27/2012WO2012150829A3 Noble triazolopyridine derivative or pharmaceutically acceptable salts thereof, production method thereof, and pharmaceutical composition including same
12/27/2012WO2012150299A3 Treatment of hyperproliferative diseases of the urogenital tract
12/27/2012WO2012149465A3 Modulation of cd36 expression
12/27/2012WO2012149265A3 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
12/27/2012WO2012148887A9 Acute cognitive and mood effects of plant polysaccharides in adult human subjects
12/27/2012WO2012147102A4 Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
12/27/2012WO2012145597A3 Recombinant virus products and methods for inhibition of expression of myotilin
12/27/2012WO2012145520A3 Carbon monoxide releasing molecules and uses thereof
12/27/2012WO2012145392A3 Saccharide conjugates
12/27/2012WO2012145119A3 Low inflammatory blended oils
12/27/2012WO2012142474A3 N-acetyl beta alanine methods of use
12/27/2012WO2012142457A8 Macrolactam compounds and methods for the treatment of malaria
12/27/2012WO2012141796A3 Prostate cancer therapy with hsp90 inhibitory compounds
12/27/2012WO2012139137A3 Pepducin design and use
12/27/2012WO2012136834A9 Pyrimidine derivatives for the treatment of viral infections
12/27/2012WO2012136204A3 Preparation for improving the alcohol metabolism
12/27/2012WO2012135817A3 Microrna 130a,b as a tumor suppressor and sensitizing agent for chemotherapy
12/27/2012WO2012135814A3 Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
12/27/2012WO2012135808A3 Intraoperative and blood-derived adhesives
12/27/2012WO2012135641A3 Aurora kinase inhibitors and methods of making and using thereof
12/27/2012WO2012135597A3 Novel, protective, anti-inflammatory receptor and its use in preservation of mitochondrial function, wound healing and repair
12/27/2012WO2012135588A3 Methods of treating serosal cancer
12/27/2012WO2012135081A3 Lin28-mediated control of let-7 biogenesis
12/27/2012WO2012135047A3 Methods and compositions for preparing noribogaine from voacangine
12/27/2012WO2012129564A3 Proteasome chymotrypsin-like inhibition using pi-1833 analogs
12/27/2012WO2012128530A3 2-methyl-2-alkyl-6-amido-2h-benzopyran derivatives having anti-cancer activity
12/27/2012WO2012128501A3 Pharmaceutical composition containing, as an active ingredient, m-3m3fbs, which is an activator of phospholipase c, for preventing or treating inflammatory diseases or infectious diseases
12/27/2012WO2012127037A3 A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
12/27/2012WO2012125864A3 Overcoming resistance to erbb pathway inhibitors
12/27/2012WO2012125749A3 INFLAMMATION AND AUTOIMMUNE DISORDER TREATMENT USING RARα SELECTIVE AGONISTS
12/27/2012WO2012125413A3 Compositions for ameliorating systemic inflammation and methods for making and using them
12/27/2012WO2012125007A3 Methods and compositions for the treatment, prevention, and alleviation of bone and cartilage diseases or injuries and hair loss
12/27/2012WO2012122383A3 Pi3 kinase inhibitors and uses thereof
12/27/2012WO2012121682A3 Anti-folate antimalarials with dual-binding modes and their preparation
12/27/2012WO2012116254A3 Chrysophaentin analogs that inhibit ftsz protein
12/27/2012WO2012116237A3 Heterocyclic compounds and uses thereof
12/27/2012WO2012112982A3 Hydrogel encapsulated cells and anti-inflammatory drugs
12/27/2012WO2012112447A3 Histone deacetylase inhibitors and methods of use thereof
12/27/2012WO2012095548A9 Dream inhibitors for treating neurodegenerative diseases
12/27/2012WO2012093137A9 Liposome formulation suitable for treating or preventing tuberculosis
12/27/2012WO2012075396A3 Prodrugs of 6-cyclohexyl-1-hydroxy-4- methylpyridin-2(1h)-one and derivatives thereof
12/27/2012WO2012071509A3 Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
12/27/2012WO2012065139A8 Entpd5 inhibitors
12/27/2012WO2012058642A3 Use of sam68 for modulating signaling through the tnf receptor
12/27/2012WO2011159770A3 Methods and compositions for promoting hair growth
12/27/2012WO2011115725A3 Indazole compounds as kinase activity modulators for the treatment of cancer and related disorders
12/27/2012WO2011108963A8 Urethanes, ureas, amidines and related inhibitors of factor xa
12/27/2012WO2011100838A9 Derivatives of l-plienyl-1.5-diliydio-benzo[b] [1.4]diazepine-2.4-dione as inhibitors of hiv replication
12/27/2012WO2011097269A9 Crystallization method and bioavailability
12/27/2012WO2010141693A3 Borinic compositions
12/27/2012US20120330019 Hepatitis C Virus Inhibitors
12/27/2012US20120329880 Method of preparing oil suspensions of carotenoid with low viscosity and high fluidity and use thereof
12/27/2012US20120329879 Beta-adrenergic receptor agonists and uses thereof
12/27/2012US20120329878 Phenotyping tumor-infiltrating leukocytes
12/27/2012US20120329877 Cycloalkyl-dione Derivatives And Methods Of Their Use
12/27/2012US20120329876 Method and composition for stable and controlled delivery of (-)-hydroxycitric acid
12/27/2012US20120329875 Ibuprofen for Topical Administration
12/27/2012US20120329874 Synergetic composition comprising flavouring substances and organic acids and use thereof
12/27/2012US20120329873 D-serine for the treatment of visual system disorders
12/27/2012US20120329872 Ready-To-Eat Feed For Domestic Pets
12/27/2012US20120329871 Antimicrobial compounds
12/27/2012US20120329870 Methods for Treating or Preventing Restenosis and Other Vascular Proliferative Disorders
12/27/2012US20120329869 Benzyloxy anilide derivatives useful as potassium channel modulators
12/27/2012US20120329868 Paraconic acids as pigmentation activators
12/27/2012US20120329867 Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation
12/27/2012US20120329866 Therapeutic compounds
12/27/2012US20120329865 MOLECULES RELATED hERG ION CHANNELS AND THE USE THEREOF
12/27/2012US20120329864 Synergistic effect of tocotrienols and curcumin
12/27/2012US20120329863 Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
12/27/2012US20120329862 Novel compound having inhibitory effect on lipase
12/27/2012US20120329861 Treatment of cancer using benzoic acid derivatives
12/27/2012US20120329860 Uses of Beta-Nicotinamide Adenine Dinucleotide
12/27/2012US20120329859 MicroRNA Fingerprints During Human Megakaryocytopoiesis
12/27/2012US20120329858 Modified oligonucleotides for telomerase inhibition
12/27/2012US20120329857 Short Hairpin RNAs for Inhibition of Gene Expression
12/27/2012US20120329856 Methods And Compositions For Reducing Viral Genome Amounts In A Target Cell
12/27/2012US20120329855 Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
12/27/2012US20120329854 Methods and Compounds for the Diagnosis and Treatment for Cancer
12/27/2012US20120329853 Microrna-based method for anti-colorectal cancer effects and prognosis of colorectal cancer
12/27/2012US20120329852 Composition for preventing the occurrence of cardiovascular event in multiple risk patient
12/27/2012US20120329851 D-serine transporter inhibitors as pharmaceutical compositions for the treatment of central nervous system disorders
12/27/2012US20120329850 Methods for treating retinopathy with extended therapeutic effect
12/27/2012US20120329849 Unit dose formulations of ketorolac for intranasal administration
12/27/2012US20120329848 Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
12/27/2012US20120329846 Therapeutic agent for inflammatory bowel disease and tnf-alpha production inhibitor
12/27/2012US20120329845 Pharmaceutical composition
12/27/2012US20120329844 Valsartan salts
12/27/2012US20120329843 Fatty acid amide hydrolase inhihibitors for treating pain
12/27/2012US20120329842 Small molecule compounds as broad-spectrum inhibitors of metallo-beta-lactamases
12/27/2012US20120329841 Treating cancer with desthiazolyl ritonavir
12/27/2012US20120329840 Novel modulators of sphingosine phosphate receptors
12/27/2012US20120329839 Novel modulators of sphingosine phosphate receptors
12/27/2012US20120329838 Novel modulators of sphingosine phosphate receptors
12/27/2012US20120329837 Cathepsin inhibitors for treating microglia-mediated neuron loss in the central nervous system
12/27/2012US20120329836 Methods for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
12/27/2012US20120329835 Use of 1-hydroxy-2- pyridones for the treatment of seborrheic dermatitis
12/27/2012US20120329834 Compounds for the treatment of mitochondrial diseases
12/27/2012US20120329833 Use of antagonists of the cbi receptor for the manufacture of a composition useful for the treatment of hepatic diseases
1 ... 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 ... 7860